MediLink Therapeutics, a biotech firm focused on developing next-generation drug conjugates with independent intellectual property, has secured a significant $570.0M in new funding.
This substantial capital injection will accelerate its international efforts to create competitive drug conjugates, which are designed to offer better therapeutic windows for unmet clinical needs. The company aims to continuously upgrade its technologies, establish diverse technology platforms, and expand into new disease areas to serve global patients.















